An Effective Virtual Screening Protocol To Identify Promising p53-MDM2 Inhibitors

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• The interaction between p53 and MDM2 is crucial for regulating p53's tumor suppressor activity.
• Disrupting the p53-MDM2 complex can restore p53 function, presenting a therapeutic strategy for cancer.
• Existing knowledge of MDM2-ligand X-ray structures provides a basis for structure-based drug design.

Purpose of the Study:

• To develop a virtual screening protocol for identifying novel inhibitors of the p53-MDM2 interaction.
• To discover small molecules capable of blocking the p53-MDM2 interaction and reactivating p53.
• To validate the efficacy of identified compounds through in vitro assays.

Main Methods:

• Compiled a hierarchical virtual screening protocol utilizing existing X-ray crystallographic data of MDM2-ligand complexes.
• Employed docking and pharmacophore modeling for focused library selection.
• Conducted cellular vitality (MTT) and p53-MDM2 interaction assays (ELISA, co-immunoprecipitation) for compound validation.

Main Results:

• Identified a focused library of compounds through virtual screening.
• Disclosed four compounds exhibiting nanomolar inhibitory activity against the p53-MDM2 interaction.
• Validated the inhibitory potential of these compounds using biochemical and cellular assays.

Conclusions:

• The developed virtual screening protocol is effective in identifying potent p53-MDM2 inhibitors.
• The identified nanomolar inhibitors represent promising candidates for further development in cancer therapy.
• Targeting the p53-MDM2 interaction remains a viable and important strategy for cancer treatment.